LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Articles
Nps Pharmaceuticals Inc.
Headquarters:
Bedminster, NJ, United States
Website:
N/A
Year Founded:
1986
Status:
Acquired
BioCentury
|
May 24, 2021
Management Tracks
Blackstone draws on four senior advisers’ diverse experiences as deal range continues to expand
Brandicourt, Ishrak, Nader, Popovits bring expertise across fields
Read More
BioCentury
|
Jan 29, 2021
Management Tracks
Bilenker leaving Lilly’s Loxo; plus updates from Orchard, Genfit, OncXerna, Medable, Neurophth, Elevian, Biofidelity, BIO
Josh Bilenker is leaving Eli Lilly and Co. (NYSE:LLY) as CEO of Loxo Oncology to explore other opportunities, Lilly CSO and SVP Daniel Skovronsky said during the pharma’s 4Q20 earnings
Read More
BioCentury
|
May 17, 2019
Company News
May 17 Company Quick Takes: A trio of FDA approvals; plus Ligand/Cumulus, Revlimid
Read More
BioCentury
|
Apr 18, 2019
Company News
Talaris raises $100M series A, reports 70% immune tolerance for allogeneic cell therapy
Read More
BioCentury
|
Oct 20, 2017
Clinical News
EC approves Amgen's Mimpara for pediatric indication
Read More
BioCentury
|
Jul 7, 2017
Clinical News
EMA's CHMP recommends pediatric label expansion for Amgen's Mimpara
Read More
BioCentury
|
Oct 27, 2015
Company News
PTAB institutes IPRs of Bass' Gattex petitions
Read More
BioCentury
|
Sep 4, 2015
Company News
Management tracks
Read More
BioCentury
|
Aug 10, 2015
Strategy
Shire's M&A stepping stone
Totting up the leverage, risks in Shire's pursuit of Baxalta
Read More
BioCentury
|
Jul 7, 2015
Company News
Management tracks
Read More
Items per page:
10
1 - 10 of 413
Help Center
Username
Request Training
Submit Data Correction
Ask a Question
Elevio by Dixa
Help